Mainz Biomed BV Total Liabilities
Mainz Biomed BV total liabilities. Based on the latest financial reports, Mainz Biomed BV (MYNZ) has total liabilities worth $4.69 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Mainz Biomed BV defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Mainz Biomed BV (2019–2025)
Total liabilities of Mainz Biomed BV from 2019 to 2025. This chart illustrates how Mainz Biomed BV's total liabilities have evolved over time, based on quarterly financial data.
Mainz Biomed BV Competitors by Total Liabilities
The table below lists competitors of Mainz Biomed BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $1.60 Million |
|
Platinex Inc
F:9PX
|
Germany | €3.30 Million |
|
GT Biopharma Inc
NASDAQ:GTBP
|
USA | $2.22 Million |
|
Tian An Australia Ltd
AU:TIA
|
Australia | AU$188.16 Million |
|
Intanwijaya Internasional Tbk
JK:INCI
|
Indonesia | Rp73.38 Billion |
|
Cuscapi Berhad
KLSE:0051
|
Malaysia | RM21.42 Million |
|
MILA RESOUR. PLC LS-01
F:HN0
|
Germany | €116.74K |
|
Pan Entertainment Co. Ltd
KQ:068050
|
Korea | ₩50.32 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Mainz Biomed BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MYNZ total assets.
Liquidity & Leverage Metrics
Mainz Biomed BV Total Liabilities Ratios Explained
Mainz Biomed BV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mainz Biomed BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mainz Biomed BV (2019–2025)
The table below shows the annual total liabilities of Mainz Biomed BV from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.69 Million | -34.84% |
| 2024-12-31 | $7.19 Million | -40.86% |
| 2023-12-31 | $12.16 Million | +97.88% |
| 2022-12-31 | $6.14 Million | +67.00% |
| 2021-12-31 | $3.68 Million | +7.75% |
| 2020-12-31 | $3.41 Million | +28.08% |
| 2019-12-31 | $2.67 Million | -- |
About Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more